

Clinical Updates in Renal Cell Carcinoma from Madrid

Emerging Therapy for Pretreated Advanced Clear Cell Renal Cell Carcinoma

References

Tweet 2 References:

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Kidney cancer (v1.2024). Updated June 21, 2023. Accessed October 27, 2023.

https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf

Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. *Lancet*. 2011;378(9807):1931-1939. doi:10.1016/S0140-6736(11)61613-9

Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. *Lancet Oncol*. 2013;14(6):552-562. doi:10.1016/S1470-2045(13)70093-7

Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2016;17(7):917-927. doi:10.1016/S1470-2045(16)30107-3

Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. *Lancet Oncol*. 2015;16(15):1473-1482. doi:10.1016/S1470-2045(15)00290-9

Rini BI, Pal SK, Escudier BJ, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. *Lancet Oncol*. 2020;21(1):95-104. doi:10.1016/S1470-2045(19)30735-1

Rini BI, Pal SK, Escudier B, et al. Maturation of overall survival (OS) in TIVO-3 with long-term follow-up. *J Clin Oncol*. 2022;40(suppl_16):4557. doi:10.1200/JCO.2022.40.16_suppl.4557

Albiges L, Rini BI, Peltola K, et al. Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): randomized open-label phase III LITESPARK-005 study. Abstract presented at: 2023 ESMO Congress; October 20-24, 2023; Madrid, Spain. Abstract LBA88.

Additional References:

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): kidney cancer (v1.2024). Updated June 21, 2023. Accessed October 27, 2023.

https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf

Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. *Lancet*. 2011;378(9807):1931-1939. doi:10.1016/S0140-6736(11)61613-9

Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. *Lancet Oncol*. 2013;14(6):552-562. doi:10.1016/S1470-2045(13)70093-7

Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2016;17(7):917-927. doi:10.1016/S1470-2045(16)30107-3

Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. *Lancet Oncol*. 2015;16(15):1473-1482. doi:10.1016/S1470-2045(15)00290-9

Rini BI, Pal SK, Escudier BJ, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. *Lancet Oncol*. 2020;21(1):95-104. doi:10.1016/S1470-2045(19)30735-1

Rini BI, Pal SK, Escudier B, et al. Maturation of overall survival (OS) in TIVO-3 with long-term follow-up. *J Clin Oncol*. 2022;40(suppl_16):4557. doi:10.1200/JCO.2022.40.16_suppl.4557

Albiges L, Rini BI, Peltola K, et al. Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): randomized open-label phase III LITESPARK-005 study. Abstract presented at: 2023 ESMO Congress; October 20-24, 2023; Madrid, Spain. Abstract LBA88.

Choueiri TK, Kaelin WG. Targeting the HIF2–VEGF axis in renal cell carcinoma. *Nat Med*. 2020;26(10):1519-1530. doi:10.1038/s41591-020-1093-z

Shepherd STC, Drake WM, Turajilic S. The road to systemic therapy in von Hippel-Lindau (VHL) disease: are we there yet? *Eur J Cancer*. 2023;182:15-22. doi:10.1038/sj.ki.5000221

Belzutifan. Prescribing information. Merck Sharp & Dohme LLC; 2022.

Pickering L. Invited Discussant LBA87, LBA88, and 1881O. Lecture presented at: 2023 ESMO Congress; October 21, 2023; Madrid, Spain.

Glossary

adv, advanced
AXI, axitinib
BEL, belzutifan
BEV, bevacizumab
CAB, cabozantinib
ccRCC, clear cell renal cell carcinoma
CME, continuing medical education
E, everolimus
ESMO, European Society for Medical Oncology
EVE, everolimus
fu, follow-up
Gr, grade
HTN, hypertension
IA, interim analysis
ICI, immune checkpoint inhibition
IFNa, interferon alfa
INV, investigator
IRC, independent review committee
L, lenvatinib
LEN, lenvatinib
LOT, lines of therapy
mRCC, advanced/metastatic renal cell carcinoma
NCCN, National Comprehensive Cancer Network
NP, nurse practitioner
NR, not reported
ORR, overall response rate
OS, overall survival
PA, physical assistant
PD, progressive disease
PD-(L)1, programmed cell death protein 1 or its ligand
PFS, progression-free survival
Ph, phase
RCC, renal cell carcinoma
R/R, relapsed or refractory
SOR, sorafenib
TEAE, treatment-emergent adverse event
TEM, temsirolimus
TIV, tivozanib
TKI, tyrosine kinase inhibitor
TRAE, treatment-related adverse event
tx, therapy
w/, with
VEGF, vascular endothelial growth factor
VHL, von Hippel-Lindau